Considering the role of PI3K/akt/mTOR pathway in cell metabolic control [14, 21, 22] and knowing that KRAS-mutated NSCLC cells display a distinct metabolic profile [23], it is important to understand whether the activity of these inhibitors is related to their effect at metabolic level in cells with a different KRAS mutational status. This evidence concerns the gene KRAS and non-small cell lung carcinoma.